MedTrace Logo

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lipovirtide in HIV-infected Patients

NCT04592315 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2026-05-11

No results posted yet for this study

Summary

To evaluate the safety, tolerability of single dose lipovirtide injection in HIV-infected individuals without prior antiviral treatment, and to investigate the pharmacokinetic characteristics of infected patients.

Conditions

  • HIV Infections

Interventions

DRUG

Lipovirtide Injection

Single dosage of Lipovirtide Injection

Sponsors & Collaborators

  • Institute of Pathogen Biology, Beijing, China

    collaborator OTHER

  • Shanxi Kangbao Biological Product Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Haibin Yu, MD · Beijing You'an Hospital, Beijing Medical University

  • Hao Wu, MD · Beijing You'an Hospital, Beijing Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-23
Primary Completion
2023-05-02
Completion
2023-07-11

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04592315 on ClinicalTrials.gov